SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
Rhea-AI Summary
SeaStar Medical (Nasdaq: ICU) announced that CEO Eric Schlorff will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on Thursday, February 5, 2026 at 11:30 AM ET.
Live registration is available and a replay will be posted on Monday, February 9, 2026 after 11:30 AM ET and remain available for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ICU
On the day this news was published, ICU declined 2.30%, reflecting a moderate negative market reaction. This price movement removed approximately $209K from the company's valuation, bringing the market cap to $9M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ICU is down 3.24% while close peers show mixed moves: AKTX down 7.43%, ENLV down 1.71%, NRXS up 2.64%, BOLD up 0.83%, and RNTX flat. Momentum scans only flagged FBLG up 6.90% with no news, suggesting stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | 2026 milestones update | Positive | -4.7% | Outlined 2026 revenue goals, trial completion targets, and regulatory pathway plans. |
| Jan 06 | Investor conference | Neutral | -0.4% | Announced Biotech Showcase 2026 CEO presentation and webcast replay details. |
| Dec 23 | Reverse stock split | Negative | -8.6% | Announced 1-for-10 reverse split to address Nasdaq minimum bid requirement. |
| Dec 02 | FDA enrollment change | Positive | +8.3% | FDA approved reducing SAVE registry enrollment and early safety data were favorable. |
| Nov 20 | Investor conference | Neutral | -0.4% | Announced CEO presentation at NobleCon21 with webcast and 30-day replay. |
Stock often shows negative or muted reactions to corporate updates and financing/structure actions, while clearly positive regulatory news has coincided with upside moves.
Over the last several months, SeaStar Medical has combined commercial, regulatory, and capital structure milestones. The company detailed 2026 growth plans and trial milestones on Jan 7, 2026, after earlier investor conference presentations on Jan 6, 2026 and Nov 20, 2025. A 1-for-10 reverse split announced on Dec 23, 2025 preceded regained Nasdaq bid-price compliance, while an FDA decision on Dec 2, 2025 to reduce SAVE registry enrollment supported QUELIMMUNE’s post-approval adoption.
Market Pulse Summary
This announcement highlights another investor-facing event where management presents the story to a specialized audience. It follows prior conference appearances and milestone updates, reinforcing a focus on visibility while the company advances QUELIMMUNE and related programs. Investors may watch for any follow-on regulatory decisions, commercial uptake metrics, and future financing disclosures as key checkpoints after this conference presentation and replay period.
AI-generated analysis. Not financial advice.
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time.
Interested investors and guests of SeaStar Medical can register and view the live investor presentations here: Virtual Equity Conference Registration.
A replay of the SeaStar Medical presentation will be available on Monday, February 9th after 11:30 am Eastern Time on the Company's website and can be accessed here. The replay will be available for up to 30 days following its posting.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
FAQ
When will SeaStar Medical (ICU) present at the Noble Capital Markets Emerging Growth Virtual Equity Conference?
How can investors watch the SeaStar Medical (ICU) live presentation on February 5, 2026?
When and where will the replay of the SeaStar Medical (ICU) presentation be available?
Who will represent SeaStar Medical (ICU) at the February 5, 2026 presentation?
How long will the SeaStar Medical (ICU) replay remain available after posting on February 9, 2026?
